Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2014-12-31
2015-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Anakinra on Insulin Secretion
NCT01285232
Interleukin-1 Receptor Antagonist and Insulin Sensitivity
NCT00928876
Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise
NCT01771445
Glucotoxicity and Acute Exercise
NCT01771614
Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes
NCT00168519
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control (CON)
Placebo will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
Control (CON)
Anakinra (AN)
100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
Anakinra (AN)
Exercise (EX)
1 hour of cycling exercise will be performed at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
Exercise (EX)
Anakinra + Exercise (ANEX)
100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus followed by 1 hour of cycling exercise at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
Anakinra (AN)
Exercise (EX)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anakinra (AN)
Exercise (EX)
Control (CON)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Age \<30 or \>80 y
* BMI \<25 or \>40 kg/m2
* Pregnancy
* Evidence of chronic haematological/renal/hepatic/pulmonary/heart disease
* \>2kg weight change in prior 6 months
* Alcohol consumption (men: \>14 drinks/week; women: \>7 drinks/week)
* Smoking
* Physical activity of \>150 min/week
* Contraindication to exercise
* Contraindication to use of anakinra
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas Solomon
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas P Solomon, PhD
Role: PRINCIPAL_INVESTIGATOR
Rigshospitalet & University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANEX
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.